Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative cell and gene therapy (CGT) solutions for research and development (R&D), including: disease model development, AAV discovery, drug efficacy studies, and more. The company has established extensive cooperations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles, many of which were in the three major journals of CNS (Cell, Nature, Science). From its robust foundation in animal model development, to implementation of artificial intelligence (AI)-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.
One-Stop Solutions for All Research Model Needs
Our comprehensive services cover the entire process of model generation: from transgenic/gene targeting strategy design, through model development, breeding, cryopreservation, and phenotype analysis. Our CRO service platforms provide everything required for drug discovery and preclinical research, including specialty cell and gene therapy (CGT) therapeutic areas, such as ophthalmology, immuno-oncology, and neuroscience.
Expertly customized mouse and rat models